1. POOLED RESULTS OF THREE ANNUAL COHORTS FROM AN OBSERVATIONAL PROSPECTIVE STUDY DESCRIBING BRENTUXIMAB VEDOTIN USE IN ROUTINE PRACTICE IN FRANCE FOR HODGKIN LYMPHOMA: INTERIM ANALYSIS. (12th June 2019) Authors: Sibon, D.; Quittet, P.; Borel, C.; Stamatoullas, A.; Franchi‐Rezgui, P.; Ghesquieres, H.; Dulery, R.; Benbrahim, O.; Hammoud, M.; Durot, E.; De Guibert, S.; Coulibaly, C.; Casasnovas, O.; Bouabdallah, R.; Brice, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 492 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1569 Benefit of a lower dose of Epoetin Theta (ET) in real life for the treatment of chemotherapy-induced anemia (CIA). (September 2015) Authors: Bugat, R.; Rouge, M.E.; Mouysset, J.L.; Badinand, D.; Assaf, E.; Fleck, E.; Guita, S.; Hussam, S.; Benbrahim, O.; Askoul, W. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY. (23rd June 2022) Authors: Cartron, G.; Bachy, E.; Tilly, H.; Daguindau, N.; Pica, G.-M.; Bijou, F.; Mounier, C.; Clavert, A. M.; Damaj, G. L.; Slama, B.; Casasnovas, O.; Houot, R.; Bouabdallah, K.; Sibon, D.; Fitoussi, O.; Morineau, N.; Herbaux, C.; Gastinne, T.; Fornecker, L.-M.; Haioun, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1023 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗